Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation

Conclusions This is the first report detailing a response to treatment with sunitinib of a gastrointestinal stromal tumor with an uncommon exon 12 PDGFRA mutation. Based on the observed efficacy, GIST patients with this rare molecular subtype should be considered for sunitinib therapy.

http://link.springer.com/10.1186/s13569-015-0036-9

Source: Clinical Sarcoma Research - September 21, 2015 Category: Cancer & Oncology Source Type: research